14 tracked fund houses held AUROPHARMA in Aug 2026. NJ Mutual Fund entered; ICICI Prudential Mutual Fund exited.
All tracked schemes together held 5.67 cr shares, 9.85% of equity, worth ₹9,729 cr at the end of Aug 2026.
Index and arbitrage funds held 0.93% of equity; they are left out of the fund-house counts.
Top buyer Nippon India Mutual Fund, +0.02% of equity. Top seller ICICI Prudential Mutual Fund, −0.14% of equity. Index and arbitrage funds hidden.
FPI category I + II, % of total shares · 0 named at 1% or more
No FPI held 1% or more of AUROPHARMA on 30 Jun 2026.
of promoter holding · 7.14% of total shares
Promoters had pledged 4.11 cr of their 29.85 cr shares on 30 Jun 2026; 4.11 cr encumbered in all (pledge, NDU and other).
percentile 100 of 30 days collected
22,666 shares, under 0.01% of equity in SLBS open positions at the end of 25 Sep 2026; that day sits at percentile 100 of 30 days collected. No SLBM trades in AUROPHARMA on 25 Sep 2026.
percentile 3 of 29 days collected · ₹45.1 cr financed
3.05 lakh shares, 0.05% of equity in the margin trading book at the end of 24 Sep 2026; that day sits at percentile 3 of 29 days collected.
20-day average 48.2% · percentile 33 of 30 days collected
46.2% of the shares traded on 25 Sep 2026 were delivered, against a 20-day average of 48.2%; that day sits at percentile 33 of 30 days collected.
MWPL used 30.7% on 25 Sep 2026 · ban above 95%, lifted below 80%
AUROPHARMA was not in the F&O ban period on 25 Sep 2026; 30.7% of its market-wide position limit was used on 25 Sep 2026. In the ban on 0 of 30 days collected. NSE listed AUROPHARMA under no ASM or GSM stage on 25 Sep 2026. Pledge invocations are not collected yet.